Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

Background: Evidence of osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC) are currently lacking. This case series study aimed to assess the safety and feasibility of neoadjuvant osimertinib therapy followed by surgery for resectable NSCLC. Materials and methods: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yan, Ren, Siying, Yang, Lulu, Tong, Zhongyi, Wang, Ruoyao, Han, Wei, Zeng, Chao, Li, Jina, Xiao, Peng, Wang, Li, Yu, Fenglei, Liu, Wenliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096023/
https://www.ncbi.nlm.nih.gov/pubmed/35571073
http://dx.doi.org/10.3389/fphar.2022.912153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096023/
https://www.ncbi.nlm.nih.gov/pubmed/35571073
http://dx.doi.org/10.3389/fphar.2022.912153

Ejemplares similares